CTI BioPharma: NCCN Recommends VONJO For Myelofibrosis Patients Regardless Of Platelet Count

WASHINGTON (dpa-AFX) - CTI BioPharma Corp. (CTIC) said VONJO (pacritinib) has been included as a recommended treatment in the latest National Comprehensive Cancer Network Clinical Practice Guidelines

Related Keywords

Washington ,United States ,Adam Craig ,Biopharma Corp , ,Biopharma ,Nccn ,Ecommends ,Honjo ,Myelofibrosis ,Patients ,Regardless ,Platelet ,Count ,